poisar

Stocks · News reference

A Federal Judge In Manhattan Ruled For Novartis On Wednesday Against Allegations That It Misused One Of Its Patents To Maintain Its Exclusivity On Its Blockbuster Heart-Failure Drug Entresto

Benzinga Newsdesk

-Reuters

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NVS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

    The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

    ABBVJNJPFENVSRHHBY
  2. Na

    Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

    Ionis Pharmaceuticals announced positive phase III results for two partnered programs: ulefnersen (FUSION study) for FUS-ALS met its primary endpoint with Otsuka planning regulatory discussions, and sefaxersen (IMAgINATION study) for IgAN showed statistically significant proteinuria reductions with Roche continuing the trial. These wins come after recent clinical setbacks in cardiovascular programs but follow FDA approval of Zanvastro for Alexander disease.

    IONSRHHBYAZNNVS